Functional Genomics, Epigenetic Monitoring and Psychological Evidence in Personalised Healthcare.

Section 01

The Healthcare Translation Chain

Healthcare often begins when an individual tries to explain what is happening to them.

That explanation may involve pain, fatigue, anxiety, low mood, emotional instability, executive dysfunction, sensory overload, poor concentration, impulsivity, appetite changes, sleep disruption, social difficulty, physical symptoms, medication effects or changes in daily functioning.

In some cases, the individual can describe these experiences clearly. In many cases, they cannot. They may not know which details matter. They may not know whether their experience is physical, psychological, neurodevelopmental, hormonal, environmental, genetic, medication-related or stress-related. They may not remember when patterns began. They may minimise symptoms. They may overemphasise the most recent crisis. They may mask, compensate or describe the consequence rather than the cause.

The result is a translation problem.

The individual has lived experience. The clinician needs clinically useful evidence.

The route between the two is often short, pressured and incomplete.

1.1 Experience to self-description

The first translation occurs inside the individual.

A person must notice their own patterns and turn them into language. This is not straightforward.

Many health and neurodevelopmental patterns are not experienced as clean diagnostic categories. A person may experience being overwhelmed, late, exhausted, reactive, unable to focus, unable to start tasks, unable to stop worrying, unable to regulate emotion, unable to sleep, unable to tolerate sensory input, unable to maintain relationships, unable to explain physical symptoms or unable to understand why life feels more difficult than it appears to be for others.

Those descriptions are real, but they are not yet structured evidence.

A clinician may need to know:

• when the pattern began;
• whether it was present in childhood;
• whether it changes by environment;
• whether it is episodic or constant;
• whether it affects work, education, relationships or self-care;
• whether family history is relevant;
• whether medication response is unusual;
• whether sleep, diet, hormones, stress or substances contribute;
• whether the presentation overlaps with another condition;
• whether risk or crisis is present.

The person experiencing the issue may not know how to organise that information.

This means the first weakness in the healthcare translation chain is not clinical failure. It is evidence formation.

The individual may not arrive with the information needed to support the decision they are asking the system to make.

1.2 Self-description to clinical interpretation

The second translation occurs between the individual and the healthcare professional.

The individual describes. The clinician interprets.

This interpretation may be skilled, careful and clinically appropriate, but it is still constrained by available information. A short appointment may not allow a full developmental history, medication history, family history, lifestyle profile, symptom timeline, psychological profile and biological context to be explored.

In mental health and neurodevelopmental care, the same outward presentation may have several possible explanations.

Poor concentration may relate to ADHD, anxiety, depression, trauma, sleep disruption, thyroid dysfunction, medication side effects, burnout, substance use or environmental overload.

Emotional instability may relate to mood disorder, trauma, autistic burnout, ADHD-related dysregulation, hormonal change, stress, sleep deprivation or adverse medication response.

Social difficulty may relate to autism, anxiety, trauma, depression, sensory processing, communication differences or learned avoidance.

The issue is not that clinicians cannot distinguish these possibilities. The issue is that they require evidence, time and context to do so.

Where that evidence is absent, the decision pathway may become less precise.

1.3 Interpretation to pathway or treatment

The third translation is from clinical interpretation into action.

That action may be reassurance, blood testing, referral, watchful waiting, therapy, medication, lifestyle advice, crisis support, private assessment, specialist assessment or no further action.

Each route has consequences.

A referral may lead to a long wait. A medication may help, fail or create side effects. A missed referral may delay recognition. A label may provide clarity, or it may oversimplify. A private assessment may be faster but not always integrated into public care. A person who does not meet a threshold may receive little support while still experiencing significant difficulty.

This is where the translation chain becomes a risk chain.

If the source information is incomplete, the downstream action may be incomplete.

1.4 Where information is lost

Information can be lost at several points.

The research implication is clear.

A better healthcare evidence environment should not wait until the clinical appointment to begin organising information.

It should help the individual build structured evidence before they enter the pathway.

Section 02

Mental Health and Neurodevelopmental Pathway Pressure

The healthcare translation chain becomes more fragile when the system around it is under pressure.

Mental health, autism, ADHD and wider neurodevelopmental pathways in the United Kingdom are experiencing high demand, long waits and uneven access. This matters because delay does not simply postpone a label or appointment. It postpones understanding, support, treatment decisions and self-management.

When an individual is waiting for assessment, they may continue to experience distress, functional impairment, occupational difficulty, educational difficulty, relationship strain, medication uncertainty or worsening mental health. They may also attempt to interpret their own symptoms without structured support, relying on internet research, informal community knowledge, workplace feedback, family interpretation or private-sector routes of variable quality.

In this context, the quality of pre-assessment evidence becomes important.

A person may not be seen quickly, but their experience is still developing. Their symptoms, functioning, stressors, medication effects, sleep patterns and coping strategies continue to change. If those changes are not captured, the eventual assessment may depend heavily on memory, crisis-point narration or a short account of a long and complex history.

2.1 ADHD and autism assessment pressure

ADHD and autism assessment pathways provide a clear example of the problem.

Both conditions require careful assessment. Both can present differently across age, sex, environment and coping strategy. Both may be masked, misunderstood or confused with other mental health presentations. Both can involve long histories that are difficult to reconstruct during a short appointment.

The UK government has launched an independent review into mental health, autism and ADHD services, citing rising demand, inequalities in access and long waits. The announcement stated that thirteen times more people were waiting for an autism assessment in September 2025 than in April 2019. That is a significant indicator of pathway pressure.

NHS Digital also publishes recurring autism diagnostic pathway waiting-time statistics. The existence of that dataset is itself important. It shows that autism assessment waiting times are not anecdotal only; they are formally tracked as a national service issue.

The Children’s Commissioner has similarly highlighted long waits for assessment and support for autism, ADHD and other neurodevelopmental conditions, including children and families waiting extended periods for help.

The research implication is:

Where assessment pathways are delayed, individuals need better ways to organise, preserve and communicate evidence while they wait.

2.2 Mental health pathway pressure

Mental health pathways face similar pressure.

An individual seeking support for anxiety, depression, emotional dysregulation, trauma, sleep disruption, burnout, panic, obsessive thinking, low motivation or suicidal ideation may enter the system through a GP appointment, self-referral route, emergency route, talking therapies service, private therapy, occupational health or crisis support.

Each route has different thresholds, evidence expectations and time constraints.

NHS Talking Therapies data is useful in this context because it shows that mental-health pathways are already measured through referrals, activity, waiting times, outcomes and recovery. This confirms that the system is not only concerned with diagnosis, but with throughput, access, improvement and measurable outcome.

However, an individual entering mental health support may still lack a structured evidence record. They may know how they feel today, but not have an organised timeline of symptom changes, environmental triggers, medication effects, sleep patterns, genetic predisposition, family history or previous intervention outcomes.

That lack of structure matters because mental health symptoms are often dynamic.

A person’s state may change with work stress, bereavement, hormonal shifts, medication, substance use, social environment, physical illness, sleep disruption, diet, exercise, trauma exposure or seasonal pattern. A single appointment may capture only one point in that changing picture.

The research implication is:

Mental health assessment benefits from longitudinal evidence because symptoms change over time and across context.

2.3 Waiting without evidence

Waiting is not passive.

During long waiting periods, people often try to manage their own health. They may change diet, supplements, medication adherence, work patterns, sleep routines, alcohol use, exercise, social contact, therapy access or coping strategies. They may also deteriorate.

Without structured monitoring, those changes can be difficult to evaluate.

A person may arrive at a later appointment unable to explain:

• which symptoms changed;
• which interventions helped;
• which interventions worsened the situation;
• whether medication caused side effects;
• whether sleep or stress changed the presentation;
• whether symptoms were episodic, cyclical or constant;
• whether functioning improved or declined;
• whether risk escalated.

This creates a missed evidence opportunity.

The waiting period could produce useful longitudinal data. Instead, it often produces frustration, memory burden and crisis escalation.

A better model would help individuals capture structured evidence during the waiting period, so that time is not lost entirely.

2.4 Private assessment and variable confidence

Where public pathways are delayed, individuals may seek private assessment.

Private routes can be valuable. They may provide faster access, specialist time and earlier support. However, private assessment can also create uncertainty if outputs are not integrated into NHS care, if assessment standards vary, if follow-up is limited, or if the individual remains responsible for translating the private finding back into public care, employment support or medication management.

The problem is not private assessment itself. The problem is inconsistent evidence continuity.

An individual may hold documents from a private provider, self-report questionnaires, GP notes, school reports, workplace concerns, therapy notes, medication history and personal journals, but these may not sit in one coherent evidence structure.

A digital evidence layer could help by organising the information around stable domains:

• symptoms;
• functioning;
• developmental history;
• family history;
• biological tendencies;
• medication response;
• lifestyle context;
• environmental triggers;
• longitudinal change;
• professional observations;
• safety concerns.

This would not guarantee diagnostic certainty. It would improve evidence quality.

2.5 Pathway pressure creates a case for pre-assessment support

The stronger research conclusion is not that digital systems should replace clinical assessment.

It is that pathway pressure increases the need for better preparation before assessment.

A pre-assessment evidence layer could help individuals:

• understand their own patterns;
• record symptoms over time;
• identify medication concerns;
• prepare for appointments;
• communicate more clearly with clinicians;
• avoid repeating the same history across services;
• distinguish stable tendencies from changing states;
• recognise when urgent support is needed.

It could help clinicians by providing:

• structured summaries;
• longitudinal symptom data;
• prior medication-response information;
• family and developmental history prompts;
• risk flags;
• user-reported outcomes;
• relevant genomic or pharmacogenomic context where evidence supports use.

The research finding is therefore:

Pathway pressure does not justify unsafe automated diagnosis. It justifies better evidence capture before clinical decision-making.

Section 03

The Limits of Psychological Profiling Alone

Psychological profiling is essential.

Questionnaires, interviews, clinical histories, structured assessments, screening tools, behavioural observations and validated symptom scales are central to mental health and neurodevelopmental care. They help identify symptom patterns, functional impairment, developmental history, risk, distress and support needs.

The issue is not that psychological profiling is weak or unnecessary.

The issue is that psychological profiling alone may be incomplete when it is isolated from longitudinal data, biological context, medication-response information and environmental change.

A person is not only a symptom score. A person is also a biological system, a developmental history, a medication responder, an environmental participant and a changing health state.

3.1 Symptom overlap

Many conditions overlap at the level of experience.

Poor concentration may appear in ADHD, anxiety, depression, trauma, sleep deprivation, chronic stress, substance use, medication side effects, hormonal change or physical illness.

Low mood may appear in depression, burnout, grief, chronic pain, neurodivergent exhaustion, inflammatory illness, social isolation, medication effects or endocrine dysfunction.

Sensory overload may appear in autism, anxiety, trauma, migraine, sleep deprivation, occupational stress or environmental sensitivity.

Emotional dysregulation may appear in ADHD, trauma, mood disorder, personality disorder, autistic burnout, hormonal fluctuation, substance use or medication reaction.

A psychological profile can capture the presentation, but it may not fully explain the underlying contributor.

This creates the risk of premature explanation.

3.2 Masking, compensation and under-reporting

Psychological assessment can also be affected by masking and compensation.

Some individuals under-report symptoms because they have normalised them. Others have spent years compensating. Some may present well during appointments but collapse afterwards. Some may have built routines around their difficulties and therefore underestimate impairment. Others may describe the consequences of their condition rather than the condition itself.

This is particularly relevant in neurodevelopmental contexts.

A person may not say “I have executive dysfunction.” They may say “I am lazy,” “I cannot keep up,” “I leave everything until the last minute,” or “I keep ruining things.”

A person may not say “I am masking autistic traits.” They may say “social situations exhaust me,” “I rehearse conversations,” “I copy people,” or “I do not know why normal life takes so much energy.”

The words used by the individual may not map neatly to clinical constructs.

That is why structured evidence capture matters.

3.3 Comorbidity and diagnostic uncertainty

Mental health and neurodevelopmental presentations are often comorbid.

A person may have ADHD and anxiety. Autism and depression. Trauma and sleep disruption. Chronic illness and low mood. Medication sensitivity and panic. Hormonal fluctuation and emotional instability. Sensory overload and workplace stress.

Where several factors interact, a single psychological profile may identify distress but not clarify the full cause.

This can contribute to:

• partial diagnosis;
• delayed diagnosis;
• inappropriate medication;
• repeated referral;
• loss of confidence;
• overfocus on one symptom cluster;
• under-recognition of biological or environmental contributors.

The appropriate response is not to abandon psychological profiling.

The appropriate response is to strengthen it with additional evidence layers.

3.4 Static assessment versus changing state

Many psychological assessments are point-in-time.

They ask how a person feels now, or how they have felt over a recent period. That is valuable, but it may not capture the full pattern.

Some symptoms fluctuate daily. Some change by environment. Some are triggered by stress, sleep disruption, diet, hormonal cycle, workload, conflict, sensory exposure or medication. Some improve with structure and worsen without it. Some are hidden until the person’s coping systems fail.

Epigenetic and longitudinal monitoring are relevant here because they support the idea that health state can change over time. Epigenetics concerns changes in how genes work that may be influenced by behaviours and environment. That does not mean epigenetic testing can currently diagnose mental health conditions. It means that dynamic biological-state information may become a useful layer in future personalised healthcare models.

A responsible model should therefore distinguish:

• stable tendencies;
• current state;
• longitudinal pattern;
• clinical diagnosis;
• medication response;
• environmental influence.

Psychological profiling alone may struggle to separate those domains.

3.5 Psychological evidence remains essential

The limits of psychological profiling should not be overstated.

No functional genomic, epigenetic or AI-based system can responsibly replace the lived, behavioural and functional evidence captured through psychological assessment.

For mental health and neurodevelopmental conditions, symptoms, impairment, context, development and lived experience remain central.

The better model is integrated.

Psychological profiling should remain the core subjective and functional evidence layer. Functional genomics may add stable biological tendency information. Pharmacogenomics may add medication-response context. Epigenetics may add dynamic health-state signals where valid. Longitudinal tracking may show change over time.

Together, these can provide a more complete evidence base than any single layer alone.

3.6 Symptom overlap and evidence need matrix

3.7 Research finding

Psychological profiling is necessary but incomplete when used in isolation.

The research finding is:

Mental health and neurodevelopmental assessment requires structured psychological evidence, but psychological evidence becomes stronger when combined with longitudinal self-report, biological context, medication-response information and responsible interpretation of genomic and epigenetic data.

Section 04

Functional Genomics as a Lifelong Evidence Layer

Functional genomics examines how genes and their products contribute to biological function. In a personalised healthcare context, this is relevant because inherited genetic variation can influence health tendencies, disease risk, biological pathways, medication response, metabolism, inflammation, neurodevelopment, sleep, stress response and other aspects of human variability.

The important point is that genetic information is relatively stable across life.

A person’s genome does not change in the same way that mood, stress, sleep, diet, environment or symptom state may change. This makes genomic information potentially useful as a lifelong evidence layer: not because it provides simple answers, but because it may provide stable biological context that can be interpreted alongside changing psychological, environmental and clinical information.

For an Advanced Digital Health System, the strongest role for functional genomics is not standalone diagnosis. It is context.

Functional genomics may help explain why one person has a different risk profile, response pattern, medication sensitivity or biological tendency from another person.

4.1 What functional genomics can show

Functional genomics may contribute to personalised healthcare by identifying inherited variation relevant to biological function.

Depending on the test, evidence base and interpretation model, genomic information may support understanding of:

• inherited disease risk;
• metabolic variation;
• medication metabolism;
• neurodevelopmental risk context;
• immune or inflammatory tendencies;
• nutrient metabolism;
• sleep and circadian biology;
• stress-response pathways;
• cardiovascular and metabolic risk;
• family-history interpretation;
• rare or monogenic disorder investigation.

In clinical genetics, genomic testing already has established roles in some areas, especially where rare disease, developmental disorder, cancer predisposition or specific inherited conditions are suspected. In these settings, genetic testing may provide direct diagnostic or risk information.

However, the broader use of genomics for mental health, neurodivergence and personalised wellbeing is more complex. Most common mental health and neurodevelopmental presentations are not explained by a single gene. They are usually influenced by many genetic, developmental, environmental, social and psychological factors.

That makes the interpretation probabilistic rather than deterministic.

A genomic result may indicate tendency, risk or biological context. It should not be presented as destiny.

4.2 What functional genomics cannot show

Functional genomics cannot, by itself, explain a whole person.

It cannot independently diagnose most common psychiatric or neurodevelopmental conditions. It cannot determine a person’s lived experience. It cannot prove how a person functions at work, school or home. It cannot show whether a person is currently distressed. It cannot replace clinical history, psychological assessment, safeguarding review, developmental evidence or physical examination where needed.

It also cannot eliminate uncertainty.

Genetic tendencies may not express in the same way for every person. Environmental exposure, life experience, trauma, sleep, stress, socioeconomic factors, diet, medication, relationships, occupation and physical health may all influence whether and how a tendency becomes relevant.

Therefore, functional genomics must be framed carefully.

The question is not:

What diagnosis does this genome prove?

The better question is:

What biological context does this genomic information add to the person’s wider health picture?

4.3 Stable tendency versus current state

A useful ADHS model should separate stable tendency from current state.

Functional genomics is best suited to the first category.

Epigenetic testing, psychological self-report, wearable data, symptom tracking and clinical monitoring may be better suited to the second.

This separation matters because many errors arise when stable tendency is confused with present condition.

A person may have a genetic tendency without current impairment. A person may have current impairment without a clear genetic explanation. A person may have both.

The value comes from integrating the layers, not from overreading one of them.

4.4 Relevance to mental health and neurodevelopmental pathways

Functional genomics may be relevant to mental health and neurodevelopmental pathways in several ways.

First, in some neurodevelopmental presentations, genomic testing may identify rare variants, copy number variants, syndromic causes or inherited conditions that affect assessment and care planning. This is especially relevant where developmental delay, intellectual disability, congenital anomalies, epilepsy or complex multi-system presentations are present.

Second, genetic information may support family-history interpretation. Mental health and neurodevelopmental conditions often cluster in families, but family narratives can be unclear, undocumented or misunderstood. Genomic and family-history evidence may help structure that context.

Third, functional genomics may support future risk stratification. This is an emerging area and must be handled carefully, especially where polygenic risk scores or broad risk models are involved.

Fourth, functional genomics may help individuals understand that some patterns are not moral failings or personality flaws, but may relate to underlying biological variation. This can support self-understanding when framed responsibly.

The appropriate language is therefore cautious:

Functional genomics may contribute biological context to mental health and neurodevelopmental assessment, but it should not be used as a standalone diagnostic authority for complex behavioural or psychiatric presentations.

4.5 Probabilistic evidence and evidence boundaries

A responsible system must classify evidence by maturity.

Not all genomic findings have the same level of clinical meaning.

Some findings are diagnostic in a clinical genetics context. Some are risk-increasing but not determinative. Some are associated with traits but not clinically actionable. Some may be research-only. Some may be commercially promoted beyond the strength of evidence.

An ADHS-style system should therefore distinguish between:

• clinically actionable findings;
• guideline-supported findings;
• risk-associated findings;
• exploratory findings;
• non-actionable findings;
• findings requiring clinical genetics review;
• findings unsuitable for user-facing interpretation without professional support.

This boundary is essential.

Without it, the system risks creating anxiety, false reassurance, overdiagnosis or inappropriate self-treatment.

4.6 Functional genomics as personal health intelligence

The strongest use of functional genomics within ADHS is as part of a personal health intelligence profile.

That profile should not say:

“This gene means this person has this condition.”

It should say, where supported:

“This genetic information may provide context for this biological pathway, medication metabolism, inherited tendency or health risk, and should be interpreted alongside psychological, clinical, family-history and lifestyle evidence.”

This makes functional genomics useful without making it unsafe.

It also allows the system to support both individuals and clinicians. The individual gains better self-knowledge. The clinician receives a clearer evidence pack. The platform maintains responsible boundaries.

4.7 Research finding

Functional genomics can provide a stable lifelong evidence layer, but its value depends on responsible interpretation.

The research finding is:

Functional genomics should be treated as biological context, not deterministic diagnosis. When combined with psychological profiling, pharmacogenomics, epigenetic monitoring and longitudinal self-report, it can help create a more complete evidence base for personalised healthcare decision-support.

Section 05

Pharmacogenomics and Medication Decision-Support

Pharmacogenomics is one of the strongest near-term use cases for a personalised healthcare evidence system.

It examines how genetic variation affects medication metabolism, response, efficacy and adverse-effect risk. In practice, this can help explain why one person responds well to a medication while another person experiences side effects, poor response or unusual sensitivity.

This matters because many prescribing pathways still involve trial and response.

A medication is selected based on diagnosis, symptoms, guidelines, clinician judgement, patient history and safety considerations. The person then starts treatment. If it does not work, or if side effects occur, the dose may be changed, the medication may be stopped, or another medication may be tried.

That process can be clinically appropriate, but it can also be slow, frustrating and harmful where avoidable medication mismatch occurs.

Pharmacogenomics does not remove the need for prescribing judgement. It does not guarantee that a medication will work. It does not replace monitoring. But where evidence is strong, it can improve the information available before prescribing decisions are made.

5.1 Medication mismatch and adverse effects

Medication mismatch can create several harms.

A person may receive a medication that is less likely to work for them. They may metabolise it too quickly, reducing effect. They may metabolise it too slowly, increasing side-effect risk. They may experience adverse reactions that reduce adherence. They may lose confidence in treatment. They may cycle through medications while symptoms continue.

In mental health contexts, these problems can be especially serious.

A person seeking help may already be distressed, impaired or at risk. If the first medication creates intolerable side effects, emotional blunting, agitation, insomnia, gastrointestinal symptoms, sexual dysfunction, worsening anxiety or no benefit, the person may become less willing to continue treatment.

The clinical reality is that medication response is multi-factorial. It may depend on diagnosis, dose, comorbidity, other medicines, age, liver function, adherence, substance use, expectations, sleep, stress and genetics.

Pharmacogenomics is only one part of that picture.

But it is a part that can sometimes be known before medication is prescribed.

5.2 CYP2D6, CYP2C19 and antidepressant prescribing

The most defensible way to discuss pharmacogenomics is through recognised guideline areas.

For example, CPIC’s 2023 guideline provides recommendations for using CYP2D6, CYP2C19 and CYP2B6 genotype results to inform prescribing of serotonin reuptake inhibitor antidepressants. It also states that evidence for SLC6A4 and HTR2A does not support clinical use in antidepressant prescribing.

This distinction is important.

It shows that pharmacogenomics is not a blanket claim. Some gene-drug relationships are actionable. Others are not yet strong enough for clinical use.

An ADHS-style system should follow that discipline.

Where pharmacogenomic evidence is guideline-supported, it can be presented as medication decision-support. Where evidence is emerging or insufficient, it should not be presented as prescribing guidance.

5.3 Prescribing support, not prescribing authority

Pharmacogenomic information should support prescribing decisions. It should not make them independently.

A pharmacogenomic result may suggest that a person is a poor, intermediate, normal, rapid or ultrarapid metaboliser for a relevant enzyme. This may influence dose selection, medication choice or monitoring. But it does not automatically decide treatment.

The prescriber must still consider:

• diagnosis;
• symptom severity;
• clinical guidelines;
• comorbidities;
• other medications;
• contraindications;
• pregnancy or reproductive considerations;
• physical health;
• patient preference;
• prior response;
• adverse-effect history;
• safety and risk;
• monitoring requirements.

This boundary is central to responsible implementation.

The system should not output “take this medication.”

It may output:

This pharmacogenomic result may be relevant to medicines metabolised through this pathway. Clinical prescribing should consider this result alongside diagnosis, current medication, clinical guidelines and prescriber judgement.

5.4 Relevance to mental health and neurodevelopmental care

Pharmacogenomics may be useful in mental health and neurodevelopmental pathways because medications are often used over long periods and adjusted through trial and response.

This can include antidepressants, anxiolytics, antipsychotics, mood stabilisers, ADHD medications and sleep-related medications, although evidence strength varies by medication and gene.

The highest-value use cases are likely to include:

• previous adverse reactions;
• multiple medication failures;
• unusual sensitivity;
• poor response despite adherence;
• complex polypharmacy;
• family history of medication intolerance;
• medication selection before first prescription where evidence supports use;
• review of current medication where side effects are problematic.

This does not mean every person needs pharmacogenomic testing before every prescription.

It means pharmacogenomic information can reduce uncertainty in selected contexts and support more personalised medication decisions.

5.5 Pharmacogenomic decision-support boundary

5.6 Integration with personal health intelligence

Pharmacogenomics becomes more useful when integrated with other evidence.

A result may be more meaningful when viewed alongside:

• current medication;
• past medication response;
• adverse-effect history;
• symptom profile;
• diagnosis or suspected condition;
• sleep and lifestyle data;
• family medication history;
• physical health;
• clinician notes;
• user-reported outcomes.

This integrated approach is stronger than a standalone genetic report.

A standalone report may say a person has a particular metaboliser status. An integrated system can help show why that may matter in context.

For example:

• the person has had repeated side effects;
• the medication is metabolised through a relevant pathway;
• the pharmacogenomic result may explain increased exposure;
• the person should discuss this evidence with a prescriber.

That is decision-support.

5.7 Research finding

Pharmacogenomics is a strong candidate evidence layer because it can support medication decisions where gene-drug evidence is clinically valid.

The research finding is:

Pharmacogenomics should be positioned as medication decision-support, not prescribing authority. Within a governed digital health model, it can help reduce avoidable trial-and-error prescribing, improve medication conversations and support safer personalisation where recognised evidence boundaries exist.

Section 06

Epigenetic Testing as a Dynamic Health-State Layer

Epigenetics concerns changes in how genes work without changing the underlying DNA sequence.

In practical terms, epigenetic mechanisms influence whether certain genes are more or less active in particular contexts. These mechanisms can be affected by age, environment, stress, diet, lifestyle, sleep, toxins, illness and other exposures.

This makes epigenetics relevant to personalised healthcare because it sits between inherited tendency and lived state.

Functional genomics may help explain relatively stable biological predisposition. Epigenetic testing may help explain how biological systems are being influenced over time.

That distinction matters.

A person’s genetic tendency may remain stable, but their health state may change. Stress may increase. Sleep may deteriorate. Inflammation may rise. Medication may affect functioning. Lifestyle may change. Trauma or environmental exposure may alter biological regulation. Recovery may also change biological state.

A responsible digital health model should therefore distinguish between:

• what appears relatively stable;
• what appears dynamic;
• what is clinically validated;
• what is emerging;
• what should only be interpreted with caution.

6.1 What epigenetics can contribute

Epigenetic testing may contribute to personalised healthcare by providing additional information about biological state and environment-gene interaction.

Potential contribution areas include:

• biological ageing indicators;
• stress-related biological signals;
• inflammation-linked pathways;
• lifestyle and environmental exposure indicators;
• metabolic health signals;
• disease-risk research;
• treatment-response research;
• longitudinal health monitoring;
• personalised prevention and behaviour-change support.

This does not mean that epigenetic testing can currently diagnose mental health conditions or neurodevelopmental conditions.

It means that epigenetics may help explain part of the dynamic biological context in which symptoms, functioning and health risks occur.

Within an ADHS-style model, the appropriate use of epigenetic data is as a contextual health-state layer.

6.2 Environment, lifestyle and gene expression

Epigenetics is especially relevant because individuals do not experience health in isolation from environment.

Sleep, work stress, diet, exercise, social isolation, trauma exposure, substance use, pollution, medication, shift work, caregiving responsibilities and chronic illness can all influence health state.

A psychological questionnaire may capture distress or function. A genomic test may capture inherited tendency. Epigenetic data may help add information about how environment and biology are interacting.

The most useful insight may come from change over time.

For example, a person may show:

• stable inherited tendency;
• worsening sleep and stress markers;
• increased subjective anxiety;
• reduced functioning;
• medication side effects;
• changing lifestyle exposure.

No single data point proves the cause.

But together, these data may support a more informed conversation about health state, risk and intervention priorities.

6.3 Mental health and epigenetic research

Mental health and epigenetics is an active research area.

Epigenetic mechanisms have been studied in relation to stress, trauma, depression, anxiety, psychosis, neurodevelopment, substance use and treatment response. This is scientifically important because it helps explain how life experience and environment may become biologically embedded.

However, clinical translation remains limited.

For most common psychiatric and neurodevelopmental presentations, epigenetic testing is not yet a routine standalone diagnostic tool. It should not be presented as capable of proving that a person has ADHD, autism, depression, anxiety, trauma-related disorder or another psychiatric condition.

The responsible position is:

Epigenetics may support future personalised psychiatry and health-state monitoring, but current use should be framed as emerging contextual evidence unless specific clinical applications are validated.

This boundary should be visible in any ADHS-style model.

6.4 Dynamic state versus diagnosis

A key distinction is the difference between health-state monitoring and diagnosis.

Diagnosis asks whether a person meets criteria for a condition.

Health-state monitoring asks what is changing in the person’s biological, psychological or functional state.

Epigenetic testing is more naturally aligned with the second question.

It may help indicate whether certain biological pathways or markers are changing over time. It may support prevention, lifestyle intervention, monitoring or research. It may give individuals a more tangible way to understand that health is dynamic and responsive to environment.

But it does not automatically explain a psychiatric presentation.

Therefore, epigenetic outputs should be expressed carefully.

They may say:

“This marker or pattern may be associated with this biological process or exposure context.”

They should not say:

“This marker diagnoses this mental health condition.”

6.5 Evidence maturity and user safety

Epigenetic findings may be complex and easy to overinterpret.

A user-facing system must therefore classify epigenetic outputs by evidence maturity.

At minimum, outputs should distinguish:

• clinically validated markers;
• research-supported but non-diagnostic markers;
• wellness or lifestyle-associated markers;
• exploratory markers;
• markers requiring professional interpretation;
• markers not suitable for health decision-making.

This protects users from false certainty.

It also protects clinicians from receiving overclaimed reports that confuse rather than clarify the clinical picture.

The ADHS model should be designed so that epigenetic information strengthens the evidence environment, rather than creating a new layer of unsupported inference.

6.6 Longitudinal value

The strongest value of epigenetic data may be longitudinal.

A single epigenetic result may be difficult to interpret without context. Repeated results, however, may show change over time, particularly when viewed alongside structured psychological profiling, lifestyle data, medication changes and health outcomes.

For example, longitudinal monitoring may help identify:

• whether stress-related indicators are improving or worsening;
• whether lifestyle interventions correlate with biological change;
• whether subjective improvement aligns with biological markers;
• whether deterioration appears before crisis;
• whether the person’s biological state is changing after medication, therapy or environmental change.

These are not diagnostic claims. They are monitoring and decision-support claims.

That makes them more defensible.

6.7 Research finding

Epigenetic testing should be treated as a dynamic health-state evidence layer.

The research finding is:

Epigenetic testing may help personalise healthcare by adding information about environment-influenced biological state and change over time. Its role in mental health and neurodevelopmental diagnosis remains emerging, so it should be used as contextual monitoring and decision-support evidence rather than standalone diagnostic proof.

Section 07

Integrated Evidence Model

The value of an Advanced Digital Health System does not come from any single evidence layer.

Psychological profiling alone may miss biological context. Genomics alone cannot explain current lived experience. Pharmacogenomics alone cannot determine diagnosis or treatment need. Epigenetics alone cannot prove a mental health condition. Self-report alone may be incomplete. Clinical interpretation alone may be constrained by time and pathway pressure.

The opportunity is integration.

An integrated evidence model can combine stable tendencies, medication-response context, dynamic biological state, psychological presentation and longitudinal lived experience.

This creates a richer source of information for individuals and healthcare professionals.

The purpose is not to produce an automated verdict.

The purpose is to improve the quality of the evidence available for decision-making.

7.1 Evidence layers

An ADHS-style model should combine several evidence layers.

Each layer is incomplete alone.

Together, they may reduce uncertainty.

7.2 Stable tendency, dynamic state and lived experience

A responsible model should organise information into three broad categories.

Stable tendency

This includes genomic and family-history information. It may provide context about inherited risk, predisposition, metabolism and biological pathways.

Dynamic state

This includes epigenetic markers, symptoms, sleep, stress, medication effects, environment and lifestyle factors. It changes over time.

Lived experience

This includes psychological profile, functioning, impairment, relationships, work, education, coping, distress, goals and personal meaning.

These categories should be kept separate but interpreted together.

A person may have a stable tendency without current distress. A person may have distress without a clear genomic signal. A person may have dynamic state changes that explain why symptoms are worse now than previously. A person may have medication-response data that changes the prescribing conversation even if diagnosis is unchanged.

The integrated model should help clarify which evidence belongs where.

7.3 User-facing outputs

A user-facing output should help the individual understand themselves better without overclaiming medical certainty.

Outputs might include:

• structured symptom summaries;
• functional impact summaries;
• longitudinal trend reports;
• genetic tendency summaries;
• medication-response considerations;
• epigenetic health-state summaries;
• appointment preparation notes;
• questions to raise with a clinician;
• safety or escalation prompts;
• lifestyle and monitoring observations;
• evidence maturity labels.

The tone should be clear, cautious and empowering.

The system should avoid language that implies diagnosis where diagnosis has not been made.

For example, instead of:

“You have ADHD.”

A responsible system might say:

“Your structured profile shows attention, impulsivity and executive-function patterns that may be relevant to an ADHD assessment. These findings should be discussed with a qualified clinician, especially alongside developmental history and functional impact.”

7.4 Clinician-facing outputs

A clinician-facing output should be concise, structured and evidence-bounded.

Clinicians do not need a long consumer report during a short appointment. They need decision-relevant information.

A useful clinician-facing summary might include:

• presenting concerns;
• structured symptom profile;
• functional impact;
• developmental-history prompts;
• longitudinal pattern;
• risk or safety flags;
• current medications;
• previous medication responses;
• pharmacogenomic considerations;
• relevant genomic context;
• relevant epigenetic or health-state indicators;
• user goals;
• evidence limitations.

This turns the platform into a translation aid.

The individual still tells their story. The clinician still makes clinical decisions. The system helps organise the evidence.

7.5 Pre-assessment evidence pack

A pre-assessment evidence pack is one of the strongest ADHS use cases.

It could be used before:

• GP appointment;
• ADHD assessment;
• autism assessment;
• psychiatric review;
• therapy intake;
• medication review;
• occupational health assessment;
• private health consultation;
• preventative health review.

The pack should be structured enough to save time but not so prescriptive that it distorts clinical interpretation.

A useful pack might answer:

• What is the person concerned about?
• How long has it been present?
• What evidence suggests it is longstanding or recent?
• What areas of life are affected?
• What has changed over time?
• What has helped or worsened the issue?
• What medication history is relevant?
• Are there pharmacogenomic considerations?
• Are there biological-state indicators that may be relevant?
• What questions does the person want answered?
• Are there urgent safety concerns?

This can reduce the burden on the individual to improvise their entire health history verbally.

7.6 Decision-support, not decision replacement

The integrated evidence model should be explicit about its boundary.

It should not diagnose. It should not prescribe. It should not tell users to stop medication. It should not replace crisis support. It should not bypass professional assessment where assessment is needed.

It should support:

• self-understanding;
• evidence organisation;
• risk stratification;
• appointment preparation;
• prescribing discussion;
• longitudinal monitoring;
• referral quality;
• shared decision-making.

This boundary is what makes the model credible.

The stronger claim is not that ADHS can decide what someone “has”.

The stronger claim is that ADHS can improve the information available to the person and to the professionals supporting them.

7.7 Integrated evidence workflow

7.8 Research finding

The integrated evidence model is the core of the ADHS proposition.

The research finding is:

The value of ADHS is not genetic testing, epigenetic testing, AI analysis or psychological profiling in isolation. The value is a governed evidence-integration model that combines stable biological tendency, dynamic health-state monitoring, medication-response context and structured lived-experience data to support better personal and clinical decision-making.

Section 08

Problem, Risk and Outcome Matrix

The preceding sections identify the core evidence problem.

Individuals experience complex biological, psychological and functional patterns. Healthcare pathways often require those patterns to be translated into brief verbal descriptions. Clinicians then interpret those descriptions under time, pathway and evidential constraints. Psychological profiling is essential, but when used alone it may not capture inherited tendency, medication-response risk, changing biological state or longitudinal context.

The purpose of this section is to convert that issue into a practical problem-risk-outcome matrix.

The central question is:

What problems arise when healthcare evidence is fragmented, subjective or delayed, who is exposed by those problems, and what would a better evidence environment need to produce?

8.1 Problem-risk-outcome matrix

8.2 The recurring pattern

The matrix shows a repeated pattern.

The issue is not simply that healthcare systems are busy, or that individuals struggle to describe symptoms, or that clinicians lack information.

The issue is that the current evidence environment is often built too late.

Evidence is assembled at the moment of pressure: during the appointment, during the referral, during the crisis, during the prescribing decision or during the specialist assessment.

At that point, information may already be incomplete.

A better model would begin earlier. It would help individuals build structured evidence before the system asks them to explain everything in one conversation.

This is the core ADHS opportunity:

Move evidence formation upstream.

8.3 Risk categories

The problems above can be grouped into six risk categories.

A responsible solution must address all six.

It must improve evidence without pretending to remove uncertainty entirely.

8.4 Required outcome categories

A better evidence environment should produce clear outcome categories.

These categories define what ADHS should produce.

They also define what it should avoid.

It should not produce unsupported diagnostic certainty. It should produce structured, bounded and usable evidence.

8.5 Research finding

The problem-risk-outcome analysis supports a clear finding:

The current healthcare evidence environment often asks individuals and clinicians to make high-consequence decisions from fragmented, subjective or late-assembled information. A responsible digital health model should move evidence formation upstream by creating structured, longitudinal, biologically informed and evidence-bounded personal health intelligence before decisions are made.

Section 09

Parameters for a Responsible Solution

An ADHS-style system must be designed carefully.

The project sits in a sensitive area: mental health, neurodevelopment, genetic information, epigenetic testing, medication response and personal healthcare decision-making.

The opportunity is significant, but so are the risks.

A poorly designed system could overclaim diagnostic capability, cause anxiety, encourage self-treatment, confuse clinicians, misuse sensitive data or present emerging science as established fact.

A responsible system must therefore begin with clear parameters.

The purpose of ADHS should not be to replace the GP, psychiatrist, psychologist, genetic counsellor, prescriber or healthcare system.

The purpose should be to improve the evidence available to them and to the individual.

9.1 Non-replacement of clinicians

The first parameter is non-replacement.

The system should not present itself as an automated diagnostic authority. It should not independently diagnose ADHD, autism, depression, anxiety, trauma-related conditions, psychiatric disorders, physical illnesses or medication requirements.

It should support:

• preparation for assessment;
• personal understanding;
• structured symptom description;
• longitudinal monitoring;
• medication-response discussion;
• biological context;
• clinical review;
• shared decision-making.

This boundary should be visible in the product language, user interface, reports and disclaimers.

The model truth is:

ADHS is an evidence and decision-support layer, not a substitute clinician.

9.2 Evidence classification

Every output should classify the strength of evidence.

This is essential because the system may combine very different evidence types.

Some findings may be clinically validated. Some may be guideline-supported. Some may be research-supported but not diagnostic. Some may be exploratory. Some may be user-reported. Some may require professional interpretation.

A responsible classification model might include:

This prevents unsupported certainty.

9.3 Safety and escalation

A personal health intelligence system must include safety routing.

Some users may disclose crisis, self-harm risk, abuse, safeguarding concerns, medication reactions, psychosis symptoms, severe deterioration or urgent physical health symptoms.

The system must not treat these as ordinary self-insight data.

It should include clear escalation pathways, such as:

• emergency services guidance;
• crisis helpline signposting;
• GP or urgent care advice;
• safeguarding prompts;
• medication side-effect warnings;
• instruction not to stop or change prescribed medication without professional advice;
• high-risk output suppression where appropriate.

Safety routing is not an optional feature. It is a core responsibility.

9.4 Consent and privacy

Genomic, epigenetic, psychological and mental-health data are highly sensitive.

A responsible system must use strong consent and privacy controls.

Minimum requirements should include:

• explicit consent for each data type;
• clear explanation of how data will be used;
• clear distinction between user-facing and clinician-facing outputs;
• user control over sharing;
• secure storage;
• encryption;
• access controls;
• deletion rights where legally applicable;
• audit trails;
• special protection for genetic and mental-health data;
• strict limits on secondary use;
• transparent research-consent options.

A system that improves evidence but weakens privacy would fail its own purpose.

Trust is part of the intervention.

9.5 Clinical governance

ADHS should operate within a clinical governance framework if it moves beyond general wellness and into health decision-support.

This may include:

• clinical advisory oversight;
• genetic counselling input where needed;
• psychiatry and psychology review;
• pharmacogenomics expertise;
• evidence review board;
• risk and safety review;
• regulatory classification assessment;
• incident reporting;
• quality management;
• validation and evaluation;
• user feedback monitoring.

The more clinically influential the output becomes, the stronger the governance requirement.

A report used only for personal reflection carries one risk profile. A report used to support prescribing or assessment carries a higher one.

9.6 Explainability

The system should explain why an output appears.

A user should not receive a black-box statement about their health without understanding what it is based on.

A clinician should be able to see whether a statement comes from:

• user self-report;
• psychological scale response;
• genomic evidence;
• pharmacogenomic evidence;
• epigenetic marker;
• longitudinal trend;
• clinical document;
• algorithmic pattern detection;
• combined interpretation.

This is especially important where AI or machine learning is involved.

Explainability helps prevent overtrust and undertrust.

The system should make clear:

• what data was used;
• what was not used;
• what the output means;
• what it does not mean;
• whether the evidence is strong, emerging or exploratory;
• whether professional review is required.

9.7 Interoperability

The system should be capable of working with existing healthcare workflows where appropriate.

This does not mean full integration is required at the earliest stage. But the model should anticipate future alignment with:

• GP records;
• electronic health records;
• private provider records;
• pharmacy systems;
• genomics providers;
• laboratory reports;
• mental-health assessment services;
• occupational health;
• research datasets;
• user-held personal health records.

Interoperability matters because fragmented evidence is part of the current problem.

If ADHS becomes another disconnected data silo, it only partially solves the issue.

9.8 Equity and accessibility

A personalised health intelligence system should not be available only to highly resourced, highly literate or already health-aware users.

Accessibility should be designed in from the beginning.

This includes:

• plain-language outputs;
• mobile-friendly access;
• support for neurodivergent users;
• low cognitive-load interfaces;
• clear summaries;
• exportable reports;
• affordability considerations;
• cultural sensitivity;
• accessible reading levels;
• support for users with disabilities;
• careful handling of health anxiety.

A system intended to improve self-understanding should not require advanced health literacy to use safely.

9.9 Responsible solution criteria matrix

9.10 Research finding

The responsible solution parameters are clear.

An ADHS-style system should not attempt to become a standalone diagnostic authority.

It should create a structured, governed and evidence-bounded environment in which individuals can better understand themselves and clinicians can review better-organised information.

The research finding is:

A credible Advanced Digital Health System must operate as a personal health intelligence and decision-support layer. It should classify evidence, protect users, support clinicians, preserve privacy, explain its outputs and clearly distinguish between validated clinical information, emerging science and exploratory insight.

Section 10

Advanced Digital Health System Model

The preceding sections establish the basis for an Advanced Digital Health System.

The core problem is not a lack of human experience. Individuals already hold detailed lived experience. The problem is that this experience is often unstructured, difficult to explain, difficult to interpret and difficult to connect with biological, medication and longitudinal evidence.

The core opportunity is not automated diagnosis. The opportunity is evidence integration.

ADHS should therefore be positioned as a personal health intelligence and decision-support model.

Its purpose is to help individuals build a structured understanding of their health, and to help healthcare professionals review more complete evidence when assessment, referral, treatment or medication decisions are being considered.

The model truth is:

ADHS is not an automated diagnostic authority. It is a structured evidence and decision-support layer.

10.1 User health intelligence profile

The foundation of ADHS is the user health intelligence profile.

This profile should bring together information that is normally fragmented across memory, appointments, test results, personal notes, medication history, family history, laboratory reports and lived experience.

A user health intelligence profile may include:

• structured psychological profile;
• symptom and functioning history;
• developmental history prompts;
• family history;
• current medications;
• previous medication response;
• pharmacogenomic information;
• functional genomic context;
• epigenetic or dynamic health-state indicators;
• sleep, stress and lifestyle context;
• user goals and concerns;
• safety or escalation flags;
• longitudinal change over time.

The profile should not be presented as a diagnosis.

It should be presented as a structured evidence map.

The purpose is to help the individual understand what information may be relevant, what is known, what is self-reported, what is biologically informed, what is emerging and what should be discussed with a professional.

10.2 Pre-assessment evidence pack

A major ADHS use case is the pre-assessment evidence pack.

Many individuals arrive at healthcare appointments underprepared, not because they lack insight, but because the system has not helped them organise their evidence.

A pre-assessment evidence pack could support:

• GP appointments;
• ADHD assessment;
• autism assessment;
• psychiatric review;
• therapy intake;
• medication review;
• occupational health assessment;
• private consultation;
• preventative healthcare review;
• health coaching or wellbeing support.

The pack should be concise, structured and evidence-bounded.

It might include:

This shifts the appointment from first-time reconstruction to focused review.

10.3 Clinician-facing decision-support summary

The clinician-facing summary should be different from the user-facing dashboard.

A user may need explanation, context and learning support. A clinician needs clarity, relevance and evidence boundaries.

The clinician-facing summary should therefore be concise and structured.

It should answer:

• What is the user concerned about?
• What patterns have been reported?
• What is the functional impact?
• What has changed over time?
• What evidence is self-reported?
• What evidence is test-derived?
• What evidence is guideline-supported?
• What evidence is emerging or exploratory?
• What medication-response information may be relevant?
• What safety issues require attention?
• What limitations should be noted?

The summary should never attempt to instruct the clinician.

It should support professional judgement by reducing evidential friction.

The appropriate output is not:

“Diagnosis: ADHD.”

The appropriate output is:

“Structured evidence indicates attention, impulsivity and executive-function patterns relevant to ADHD assessment. Developmental history, functional impairment and clinician assessment remain required.”

This boundary keeps the system clinically responsible.

10.4 Medication-response support

Medication-response support is one of the most practical ADHS model components.

It should combine:

• current medication list;
• prior medication history;
• side-effect history;
• user-reported outcomes;
• adherence issues;
• pharmacogenomic evidence where valid;
• relevant clinical guidance boundaries;
• prescriber-facing summary.

This could help identify whether a user has experienced repeated medication mismatch, unusual sensitivity, side effects, poor response or adherence difficulty.

The system should not recommend self-directed medication changes.

It should instead produce prescriber discussion prompts, such as:

• “This medication is metabolised through a pathway where pharmacogenomic evidence may be relevant.”
• “The user reports previous adverse effects with this class.”
• “The pharmacogenomic result may support review of dose, alternative medication or monitoring, subject to prescriber judgement.”
• “Evidence for this gene-drug relationship is not strong enough for clinical guidance.”

This creates value without crossing into unsafe prescribing authority.

10.5 Longitudinal monitoring dashboard

A second major model component is longitudinal monitoring.

Many health and mental-health issues fluctuate. A one-off appointment may capture a temporary state rather than the whole pattern.

A longitudinal dashboard could track:

• mood;
• anxiety;
• sleep;
• focus;
• sensory overload;
• executive function;
• energy;
• medication effects;
• side effects;
• stress;
• lifestyle factors;
• functioning;
• interventions;
• epigenetic or health-state markers where appropriate;
• user-defined goals.

This can help identify patterns such as:

• deterioration before crisis;
• improvement after medication change;
• worsening after sleep disruption;
• symptom fluctuation by environment;
• adverse effects after dose change;
• improvement after routine changes;
• stress-linked relapse;
• mismatch between subjective and biological indicators.

The value is not prediction with certainty.

The value is pattern visibility.

10.6 Evidence maturity engine

ADHS should include an evidence maturity engine.

This is not necessarily a visible product feature, but it should be part of the model logic.

Every output should be tagged according to evidence maturity. This ensures that user-facing and clinician-facing outputs do not treat all evidence equally.

For example:

This is critical for trust.

A system that can say “we do not know” is more credible than one that overstates.

10.7 Research and system-learning value

With appropriate consent and governance, ADHS may also support research and healthcare-system learning.

Aggregated and de-identified data could help explore:

• symptom trajectories;
• medication-response patterns;
• waiting-list deterioration;
• pre-assessment evidence quality;
• longitudinal outcome trends;
• biological and psychological pattern relationships;
• user experience across pathways;
• differences in access and support needs;
• effectiveness of early self-management tools.

This must be handled carefully.

Research use should be opt-in, transparent, de-identified where appropriate and governed through clear ethical and data-protection processes.

The user’s personal health data should not become an uncontrolled commercial asset.

10.8 ADHS model components

10.9 Research finding

The Advanced Digital Health System model should be understood as a governed evidence-integration environment.

The research finding is:

ADHS is best positioned as a personal health intelligence and decision-support system that helps individuals and clinicians work from structured, longitudinal and biologically informed evidence. Its value lies in evidence integration, not automated diagnosis.

Section 11

Stakeholder Outcomes

An Advanced Digital Health System creates potential value because different stakeholders currently experience the evidence gap in different ways.

The individual experiences confusion, delay, self-translation burden and fragmented knowledge.

The clinician experiences time pressure, incomplete histories and limited pre-assessment evidence.

The health system experiences waiting-list pressure, repeat appointments, delayed support and avoidable medication mismatch.

Researchers experience fragmented real-world data.

Employers and occupational health providers may see functional difficulty without clear evidence of support needs.

Private providers may deliver assessments without consistent integration into wider care.

A better evidence environment does not solve every healthcare problem. It gives each stakeholder a clearer way to work from organised information.

11.1 Individuals and patients

Individuals are the primary beneficiaries of better personal health intelligence.

A person may feel that something is wrong, different or changing, but may not know how to explain it. They may have spent years trying to describe symptoms, justify difficulties, understand medication effects or find the right support.

ADHS could help by turning fragmented experience into structured evidence.

Potential outcomes include:

• better self-understanding;
• clearer appointment preparation;
• improved symptom tracking;
• reduced repetition of history;
• better medication-response awareness;
• earlier recognition of patterns;
• stronger evidence while waiting for assessment;
• clearer understanding of what is known, unknown or emerging.

The value is not that the person can self-diagnose.

The value is that the person can enter healthcare conversations better prepared.

11.2 GPs and primary care

GPs often sit at the front of the healthcare translation chain.

They must interpret a wide range of concerns, decide whether referral is appropriate, consider physical and mental health causes, manage medication, respond to risk and work within short appointment windows.

A structured evidence pack may support GP decision-making by providing:

• clearer presenting concerns;
• symptom timeline;
• functional impact;
• medication history;
• previous interventions;
• risk flags;
• user goals;
• biological context where relevant;
• suggested areas for clinical discussion.

This does not remove GP judgement.

It may reduce evidential friction.

Better outcome:

Primary care receives better-organised information before deciding the next step.

11.3 Psychiatrists, psychologists and specialist assessors

Specialist assessors need detailed evidence.

For ADHD, autism and many mental health conditions, assessment often benefits from longitudinal history, corroborative evidence, developmental context, functional impairment and symptom pattern over time.

ADHS could help by providing structured pre-assessment information, while keeping diagnostic authority with the specialist.

Potential value includes:

• clearer symptom organisation;
• developmental-history prompts;
• functional impact summary;
• masking and compensation indicators;
• longitudinal tracking;
• medication-response history;
• safety indicators;
• evidence boundary labels.

Better outcome:

Specialists receive a more coherent evidence base without being asked to rely on an automated diagnosis.

11.4 Prescribers and pharmacists

Prescribers and pharmacists may benefit from medication-response and pharmacogenomic evidence.

This is especially relevant where a person has:

• previous side effects;
• poor medication response;
• multiple medication trials;
• unusual sensitivity;
• polypharmacy;
• family history of medication intolerance;
• concerns about psychiatric medication;
• medication adherence issues.

ADHS could support safer medication conversations by summarising relevant medication history and gene-drug considerations where evidence allows.

Better outcome:

Medication decisions are supported by clearer prior-response and pharmacogenomic context, while prescribing authority remains with qualified professionals.

11.5 NHS and public healthcare systems

Public healthcare systems face demand, waiting-list and resource pressure.

ADHS should not be framed as a replacement for services. It should be framed as a way to improve the evidence environment before and between service contacts.

Potential system value includes:

• better prepared referrals;
• reduced repeated history-taking;
• improved interim monitoring while waiting;
• better triage information;
• earlier identification of deterioration;
• more structured medication-review evidence;
• improved patient engagement;
• improved outcome tracking.

Better outcome:

Health systems may receive more usable information earlier in the pathway, potentially improving triage, continuity and decision quality.

This requires careful validation before system-level claims are made.

11.6 Private healthcare providers

Private providers may use structured evidence to improve assessment preparation and post-assessment continuity.

Where people seek private ADHD, autism, psychiatric, psychological, genomic or preventative-health services, ADHS could help assemble a coherent pre-assessment profile and provide a portable record for later use.

Better outcome:

Private assessment and support can be better integrated with user-held evidence, reducing fragmentation between providers.

11.7 Employers and occupational health

Employers should not receive sensitive genetic, epigenetic or diagnostic information unless the individual explicitly chooses to share appropriate material.

However, occupational health may benefit from functional evidence where the user consents.

For example, a user may share a summary of:

• functional impact;
• workplace triggers;
• support needs;
• fatigue patterns;
• sensory overload;
• concentration difficulties;
• medication side effects;
• reasonable-adjustment considerations.

The system should separate occupational outputs from full medical or genetic records.

Better outcome:

Individuals can communicate support needs without disclosing unnecessary sensitive biological or diagnostic data.

11.8 Researchers and academic partners

With consent and governance, ADHS may support research into personalised healthcare, digital mental health, pharmacogenomics, epigenetics, neurodevelopmental assessment and longitudinal outcomes.

The original ADHS stakeholder document positioned Manchester Metropolitan University as a potential development partner for the technical framework and algorithms. That context remains useful as a historical project foundation, but any future research collaboration should be governed by current agreements, ethics, data protection and publication controls.

Better outcome:

Researchers may gain access to ethically governed, structured and longitudinal evidence that can support future personalised healthcare research.

11.9 Stakeholder outcome matrix

11.10 Research finding

The stakeholder analysis supports the central conclusion of the paper.

The value of ADHS is not limited to one user group. A structured evidence environment can support individuals, clinicians, prescribers, healthcare systems, private providers, occupational health and research partners in different ways.

The research finding is:

An Advanced Digital Health System can create value by reducing the burden of translation between lived experience and healthcare interpretation. Its strongest contribution is to organise evidence before decisions are made, while preserving the role of qualified professionals in diagnosis, prescribing and care planning.

Section 12

Overall Findings

This document has examined whether functional genomics, pharmacogenomics, epigenetic testing and structured psychological profiling can create a stronger evidence layer for personalised healthcare decision-making.

The research does not suggest that biological testing can replace clinical assessment. It does not suggest that genomics can diagnose common mental health or neurodevelopmental conditions in isolation. It does not suggest that epigenetic testing is currently a standalone psychiatric diagnostic tool. It does not suggest that artificial intelligence should prescribe, diagnose or replace professional judgement.

The finding is narrower.

Many healthcare, mental health and neurodevelopmental pathways rely on a fragile translation chain between lived experience and clinical interpretation. The individual must explain complex internal states, developmental history, symptoms, functioning, medication effects and changes over time. The clinician must then interpret that information within appointment, pathway and evidential constraints.

That process can work well when time, evidence and expertise are available.

It becomes weaker when information is incomplete, appointments are short, symptoms overlap, biological context is absent, waiting lists are long, medication response is uncertain or the individual cannot clearly describe what is happening.

The central conclusion is therefore:

The appropriate objective is not automated diagnosis.

The appropriate objective is evidence-assisted personal health intelligence.

12.1 Finding one: Healthcare relies on a translation chain

Healthcare often begins with the individual translating lived experience into language.

That language must then be interpreted by a clinician, mapped against clinical knowledge and converted into a pathway, intervention, referral, prescription or monitoring decision.

This creates several points of information loss.

The individual may not know which symptoms matter. They may describe consequences rather than causes. They may under-report, mask or normalise difficulties. They may remember the most recent crisis more clearly than the long-term pattern. They may not understand medication effects or biological contributors.

The clinician may be skilled, but constrained by appointment length, pathway thresholds, available records and the quality of information presented.

The research finding is:

A better healthcare evidence environment should begin before the appointment, helping individuals organise relevant information before it must be interpreted clinically.

12.2 Finding two: Mental health and neurodevelopmental pathways are under pressure

Mental health, autism, ADHD and wider neurodevelopmental pathways face rising demand, long waits and access pressure.

This matters because waiting is not neutral. During waiting periods, symptoms may change, functioning may decline, coping strategies may fail, medication may be tried, private assessment may be sought, and evidence may remain undocumented.

Pathway pressure strengthens the case for structured pre-assessment support.

A digital system should not replace assessment, but it may help users preserve evidence while they wait, improve referral quality and prepare better for clinical review.

The research finding is:

Where assessment capacity is constrained, structured evidence capture becomes more valuable, not less.

12.3 Finding three: Psychological profiling is essential but incomplete alone

Psychological profiling is central to mental health and neurodevelopmental assessment.

It captures symptoms, functioning, distress, behaviour, history and lived experience. It remains essential and cannot be replaced by genomics, epigenetics or AI.

However, psychological profiling may be incomplete when used in isolation.

It may not capture inherited biological tendencies, medication-response risk, dynamic health-state change, sleep patterns, lifestyle context, physical health interactions or long-term fluctuation.

The research finding is:

Psychological evidence should remain central, but it becomes stronger when combined with longitudinal self-report, biological context and medication-response information.

12.4 Finding four: Functional genomics can provide stable biological context

Functional genomics may provide information about relatively stable inherited tendencies, biological pathways, metabolism, predisposition and individual variation.

Its value is contextual.

It should not be used to claim deterministic diagnosis for complex mental health or neurodevelopmental presentations. Most common psychiatric and neurodevelopmental conditions are multi-factorial, involving genetic, environmental, developmental, psychological and social influences.

The research finding is:

Functional genomics should be treated as a lifelong biological evidence layer: useful for context, risk understanding and personalisation, but not a standalone diagnostic authority for complex behavioural or psychiatric conditions.

12.5 Finding five: Pharmacogenomics is a strong near-term decision-support use case

Pharmacogenomics has one of the clearest near-term applications because some gene-drug relationships can inform medication selection, dosing or monitoring.

This is particularly relevant where individuals experience side effects, poor response, repeated medication changes, unusual sensitivity or complex prescribing histories.

However, pharmacogenomics does not guarantee that a medication will work. It does not replace diagnosis, prescriber judgement, monitoring or patient preference. It should be bounded by recognised evidence and guidance.

The research finding is:

Pharmacogenomics should be positioned as medication decision-support, not prescribing authority.

12.6 Finding six: Epigenetic testing may support dynamic monitoring, but remains emerging for psychiatric diagnosis

Epigenetics may help explain how environment, behaviour, age, stress, lifestyle and exposure influence gene expression over time.

That makes it relevant to dynamic health-state monitoring.

However, the use of epigenetic testing as a routine diagnostic tool for mental health or neurodevelopmental conditions remains emerging. It should not be presented as proof of ADHD, autism, depression, anxiety, trauma or other psychiatric conditions.

The research finding is:

Epigenetic testing may contribute to personalised healthcare as contextual and longitudinal health-state evidence, but should be clearly distinguished from validated diagnostic testing.

12.7 Finding seven: The opportunity is integration

The value of ADHS does not come from any single evidence source.

Psychological profiling, functional genomics, pharmacogenomics, epigenetic testing, clinical records, self-report and longitudinal monitoring are all incomplete in isolation.

The opportunity is to integrate them responsibly.

A combined evidence model can help separate:

• stable tendency;
• dynamic health state;
• lived experience;
• medication response;
• professional observations;
• user goals;
• evidence maturity;
• clinical limitations.

The research finding is:

An integrated evidence model can reduce uncertainty by helping individuals and clinicians work from a more complete, structured and evidence-bounded picture.

12.8 Finding eight: ADHS should be a decision-support system, not a diagnostic replacement

A responsible ADHS model must be explicit about what it is and what it is not.

It should not diagnose, prescribe, replace clinicians, bypass safeguarding, encourage medication changes or present emerging evidence as clinical certainty.

It should support:

• self-understanding;
• pre-assessment preparation;
• structured symptom evidence;
• medication-response review;
• longitudinal monitoring;
• risk flagging;
• clinician-facing summaries;
• shared decision-making;
• research learning where consent and governance allow.

The research finding is:

ADHS is best positioned as an evidence-assisted personal health intelligence system. Its purpose is to organise and contextualise information before decisions are made.

12.9 Final conclusion

Healthcare decisions are only as strong as the information available at the point of decision.

In many mental health, neurodevelopmental and personalised care pathways, the available information is incomplete, late-assembled or poorly structured. Individuals may struggle to describe what is happening. Clinicians may be required to interpret complex histories quickly. Waiting lists may delay support. Medication decisions may proceed without useful pharmacogenomic context. Biological tendencies and dynamic health-state changes may remain separate from psychological evidence.

A better model would not remove clinicians from the process.

It would improve the evidence environment around them.

Functional genomics, pharmacogenomics, epigenetic monitoring and structured psychological profiling should therefore be explored as complementary evidence layers within a governed personal health intelligence system. Such a system should help individuals understand themselves, prepare for assessment, monitor change over time, support safer medication conversations and provide clinicians with clearer information while preserving professional judgement, evidence boundaries and user safety.

That is the research basis for the Advanced Digital Health System.

Appendix A

Source List

The following source list supports the research paper. Some entries are core evidence sources; others are supporting or contextual sources.

Appendix source-use hierarchy

Primary / core sources

• UK government mental health, autism and ADHD service review.
• NHS Digital autism diagnostic pathway statistics.
• NICE ADHD guidance.
• NICE autism guidance.
• Royal College of Psychiatrists adult ADHD guidance.
• CPIC pharmacogenomics guideline.
• NHS pharmacogenomics and medicines optimisation material.
• CDC epigenetics overview.
• Peer-reviewed epigenetics and psychiatry review.
• Genomic testing consensus statement for neurodevelopmental disorders.

Secondary / supporting sources

• Children’s Commissioner neurodevelopmental waiting-time report.
• NHS Talking Therapies statistics.
• NHS Genomic Medicine Service material.
• Genomics Education Programme material.
• Peer-reviewed pharmacogenomics reviews.
• Polygenic risk score literature.
• Digital mental health and AI decision-support guidance.

Contextual / legacy sources

• AUG24-ADHS-U008 stakeholder update.
• WHO mental health material.
• Broader digital health and personalised medicine commentary.

The source hierarchy is designed to ensure that the research paper relies primarily on clinical guidance, official statistics, public health sources and peer-reviewed scientific literature, while using the original ADHS stakeholder document only as historical project context.